Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Gastric Retention of LYN-PLT in Healthy Adults
NCT03718390Phase 1Completed
- Sponsor
- Lyndra Therapeutics
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Formulation C (37/50A) (5 arms), sponsored by Lyndra Therapeutics. Primary endpoints: Gastric retention assessed by Magnetic Resonance Imaging (MRI) and Safety and tolerability collected from Adverse Event (AE) reporting up to 6 months. Started Jun 2018; status: completed.
02
Drugs
Formulation C (37/50A)
Beyond the preview
Go deeper on NCT03718390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718390.